Abstract
The choice of the optimal design of investigational or commercially available cytotoxic agents for clinical trials in patients with hormone refractory prostate cancer has long been a considerable methodologic problem. The conventional endpoints for measuring therapeutic activity in solid tumors are infrequently applicable in prostate cancer. Several definitions of response have been developed which attempt to accurately identify agents with meaningful clinical activity. While promising preliminary results for chemotherapeutic agents have been reported using the various response criteria, these results have not been confirmed. When restudied no agents have been identified that could be considered standard therapy for this disease. Consistent response rates in excess of 20 percent have not been observed for any therapy in hormone refractory prostate cancer. Additionally, no survival benefit has been seen with any cytotoxic therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Greenwald, P. and Sondik, E.J. (eds), Cancer Control Objectives for the Nation: 1985–2000, in: “NCI Monographs,” No. 2, Washington, D.C., U.S. Government Printing Office, pp 3–93, 1986.
Eisenberger, M.A., Simon, R., O’Dwyer, P.J., Wittes, R.E. and Friedman, M.A. A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J. Clin. Oncol. 3:827–841, 1985.
Crawford, D. A comparison of leuprolide with leuprolide and flutamide in previously untreated patients with clinical Stage D2 cancer of the prostate. San Antonio: Southwest Oncology Group, pp 1–16, 1985.
O’Bryan, R.M., Luce, J.K., Talley, R.W., Gottlieb, J.A., Baker, L.H. and Bonnadona, G. Phase II evaluation of adriamycin in human neoplasia. Cancer 32:1–8, 1973.
O’Bryan, R.M., Baker, L.H., Gottleib, J.E., Rivkin, S.E., Balcerzak, S.P., Grumet, G.N., Salmon, S.E., Moon T.E. and Hoogstraten, B. Dose response evaluation of adriamycin in human neoplasia. Cancer 39: 1940–1948, 1977.
Torti, F.M., Aston, D., Lum, B.L., Kohler, M., Williams, R., Spaulding, J.T., Shortliffe, L. and Freiha, F.S. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J. Clin. Oncol. 1:477–482, 1983.
Scher, H., Yagoda, A., Watson, R.C., Serber, M. and Whitmore, W. Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J. Urol. 131:1099–1102, 1984.
Izbicki, R.M., Amer, M.H. and Al-Sarraf, M. Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma: A Phase II study. Cancer Treatment Report 63:999–1001, 1979.
Ihde, D.C., Bunn, P.A., Cohen, M.H., Dunnick, N.R., Eddy, J.L. and Minna, J.D. Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide. Cancer 45:1300–1310, 1980.
Merrin, C., Etra, W., Wajsman, Z., Baumgartner, G. and Murphy, G. Chemotherapy of advanced carcinoma of the prostate with fluo-rouracil, cyclophosphamide, and adriamycin. J. Urol. 115:86-88, 1976.
Lloyd, R.E., Jones, S.E., Salmon, S.E., Durie, B.G.M. and McMahon, L.J. Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: A Phase II trial. Cancer Treatment Report 60:77–83, 1976.
Soloway, M.S., Shippel, R.M. and Ikard, M. Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. J. Urol. 122:637–639, 1979.
Slack, N.H., Mittleman, A., Brady, M.F. and Murphy, G P. The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer. Cancer 46:2393–2402, 1980.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Plenum Press, New York
About this chapter
Cite this chapter
Dorr, F.A., Friedman, M.A. (1988). Clinical Trial Design for Cytotoxics in Prostate Cancer. In: Coffey, D.S., Resnick, M.I., Dorr, F.A., Karr, J.P. (eds) A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1667-1_26
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1667-1_26
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8925-8
Online ISBN: 978-1-4613-1667-1
eBook Packages: Springer Book Archive